These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 32972289)

  • 1. Evaluating the effect of oral clarithromycin on acute cutaneous leishmaniasis lesions compared with systemic glucantime.
    Zabolinejad N; Layegh P; Abbasi Shaye Z; Salehi M; Ghanizadeh S
    J Dermatolog Treat; 2022 May; 33(3):1418-1423. PubMed ID: 32972289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison Of Efficacy Of Miltefosine Versus Meglumine Antimonate In The Treatment Of Cutaneous Leishmaniasis.
    Mohammad N; Sagheer F; Paracha MM; Khan AQ; Naseem S; Wasim M
    J Ayub Med Coll Abbottabad; 2022; 34(4):849-853. PubMed ID: 36566412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
    Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
    J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.
    Layegh P; Yazdanpanah MJ; Vosugh EM; Pezeshkpoor F; Shakeri MT; Moghiman T
    Am J Trop Med Hyg; 2007 Jul; 77(1):99-101. PubMed ID: 17620637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.
    Esfandiarpour I; Alavi A
    Int J Dermatol; 2002 Aug; 41(8):521-4. PubMed ID: 12207774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective meglumine antimoniate intralesional therapy for Chiclero's ulcer refractory to systemic liposomal amphotericin B.
    Spinicci M; Zammarchi L; Gramiccia M; Di Muccio T; Bartolozzi D; Corsi P; Trotta M; Bartoloni A
    J Travel Med; 2021 Aug; 28(6):. PubMed ID: 32918547
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis.
    Asilian A; Sadeghinia A; Faghihi G; Momeni A
    Int J Dermatol; 2004 Apr; 43(4):281-3. PubMed ID: 15090013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison Of Oral Dapsone With Intramuscular Meglumine Antimoniate In Cutaneous Leishmaniasis.
    Ahmed N; Malik S; Tahir M; Rahman A; Fayyaz I; Raza N; Iftikhar N
    J Ayub Med Coll Abbottabad; 2022; 34(4):802-806. PubMed ID: 36566403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic meglumine antimoniate in acute cutaneous leishmaniasis: children versus adults.
    Layegh P; Rahsepar S; Rahsepar AA
    Am J Trop Med Hyg; 2011 Apr; 84(4):539-42. PubMed ID: 21460006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of glucantime for treatment of cutaneous leishmaniasis in Central Iran.
    Mohammadzadeh M; Behnaz F; Golshan Z
    J Infect Public Health; 2013 Apr; 6(2):120-4. PubMed ID: 23537825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucantime efficacy in the treatment of zoonotic cutaneous leishmaniasis.
    Pourmohammadi B; Motazedian MH; Handjani F; Hatam GH; Habibi S; Sarkari B
    Southeast Asian J Trop Med Public Health; 2011 May; 42(3):502-8. PubMed ID: 21706927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrocardiographic Alterations Related to Intralesional Glucantime® Treatments: A Potentially Severe Adverse Event.
    García Bracamonte B; Burillo Martínez S; Morales Raya C; Ortiz Romero P
    Actas Dermosifiliogr; 2022; 113(7):742-744. PubMed ID: 35331726
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children.
    Layegh P; Pezeshkpoor F; Soruri AH; Naviafar P; Moghiman T
    Am J Trop Med Hyg; 2009 Feb; 80(2):172-5. PubMed ID: 19190206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial.
    Velez I; Agudelo S; Hendrickx E; Puerta J; Grogl M; Modabber F; Berman J
    Ann Intern Med; 1997 Feb; 126(3):232-6. PubMed ID: 9027276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expansion of gammadelta T Cells in patients infected with cutaneous leishmaniasis with and without glucantime therapy.
    Darabi H; Abolhassani M; Kariminia A; Alimohammadian MH
    Braz J Infect Dis; 2002 Oct; 6(5):258-62. PubMed ID: 12495608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [N-methyl glucamine antimoniate or Glucantime].
    Rapp C; Simon F; Dordain ML
    Med Trop (Mars); 2000; 60(4):342-3. PubMed ID: 11436584
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis.
    Sadeghian G; Nilforoushzadeh MA
    Int J Dermatol; 2006 Jul; 45(7):819-21. PubMed ID: 16863518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the efficacy and safety of vascular IPL for treatment of acute cutaneous leishmaniasis: a randomized controlled trial.
    Tafazzoli Z; Nahidi Y; Mashayekhi Goyonlo V; Morovatdar N; Layegh P
    Lasers Med Sci; 2021 Apr; 36(3):631-640. PubMed ID: 32681219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.
    Andersen EM; Cruz-Saldarriaga M; Llanos-Cuentas A; Luz-Cjuno M; Echevarria J; Miranda-Verastegui C; Colina O; Berman JD
    Am J Trop Med Hyg; 2005 Feb; 72(2):133-7. PubMed ID: 15741547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of thermotherapy for the treatment of cutaneous leishmaniasis in Kabul, Afghanistan: a randomized controlled trial.
    Safi N; Davis GD; Nadir M; Hamid H; Robert LL; Case AJ
    Mil Med; 2012 Mar; 177(3):345-51. PubMed ID: 22479925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.